Symbiomix NDA for Treating Bacterial Vaginosis
Symbiomix has submitted an NDA for Solosec (secnidazole oral granules) for treating bacterial vaginosis (BV). The company describes Solosec as a potent, next-generation, investigational 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties. In clinical trials Solosec demonstrated efficacy for treating BV with only a single, oral, two-gram dose, it says. BV is the most prevalent gynecological infection in the U.S. among women ages 15 to 44.